Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-07 21:28:34时区推断·⟳ 抓取 08-07 21:29:11·⚡ 决策 08-08 06:03:58 +8h34m·80.7 天前
Femasys宣布3000万美元私募融资并附带低行权价认股权证
Femasys（FEMY.US）本次3000万美元融资相对其近期约千万美元级市值和2025年229万美元收入非常大，能显著缓解此前现金只够支撑到2026年三季度的融资压力。
📄 原文Investing.com↗ 原文
Femasys secures $30 million private placement financing
U.S. economy unexpectedly loses 23,000 jobs in July ATLANTA - Femasys Inc. (NASDAQ:FEMY) announced today that it has en…
不做 Femasys（FEMY.US）
私募融资同时改善现金跑道和造成显著摊薄，事件方向混合；缺少产品/临床/收入超预期增量，当前不做多，也不足以开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Investing.com转述Femasys宣布3000万美元私募融资，披露发行价、权证数量和行权价。
关键理由
- Femasys（FEMY.US）本次3000万美元融资相对其近期约千万美元级市值和2025年229万美元收入非常大，能显著缓解此前现金只够支撑到2026年三季度的融资压力。
- 但交易同时发行约937.5万股/预融资权证，并配套1875万份行权价2.95美元的认股权证，对现有股东存在明确摊薄，且不是产品获批、销售放量或临床成功这类经营催化。
- 量级上，公司2025年收入约229万美元、2026年一季度现金约540万美元；3000万美元融资改善现金跑道，但新增股份与潜在权证摊薄足以抵消短线做多逻辑。
主要风险
- 若市场把Nantahala等机构参与解读为背书，微盘股可能先出现挤压式反弹，但该事件本身更像融资重置而非经营增量。
- 未取得事件当日FEMY真实收盘/盘后报价，无法建立可回测入场价；即便有价格，也不应把低位反弹作为做多理由。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-05-08 · 影响 weakens
公司收入基数仍很小且此前现金跑道已接近2026年三季度，本次融资更像必要补血而非经营超预期。
检索:Femasys cash revenue 2025 2026 FemaSeed FemBloc revenue quarterly 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-07 · 影响 weakens
融资金额大且有摊薄，但机构参与和现金改善构成反证，净利空不足以在当前缺少真实入场价时开空。
检索:Femasys $30 million private placement August 7 2026 FEMY warrants $3.20 $2.95 原文 ↗
原文全文
展开原文 · 2,150 字
U.S. economy unexpectedly loses 23,000 jobs in July
ATLANTA - Femasys Inc. (NASDAQ:FEMY) announced today that it has entered into a securities purchase agreement for a $30 million private placement with accredited investors, according to a press release statement.
The financing is led by new institutional investor Nantahala Capital, with participation from healthcare-focused funds including Rosalind Advisors, Inc., and members of Femasys management. The transaction is expected to close on or around Sunday.
Under the agreement, the company is selling 9,374,999 shares of common stock and pre-funded warrants, along with accompanying warrants to purchase 18,749,998 shares of common stock. The purchase price per share and accompanying warrants is $3.20, while pre-funded warrants are priced at $3.1999.
Each investor will receive two accompanying warrants with a three-year term for each share or pre-funded warrant purchased. The accompanying warrants have an exercise price of $2.95 per share. Pre-funded warrants carry an exercise price of $0.0001 per share.
If all warrants are exercised for cash, the company would receive up to an additional $60 million. The milestone warrants become exercisable 12 months after closing and expire 45 days after the company achieves specified conditions, including reported U.S. revenue of at least $1.5 million in any fiscal quarter and meeting certain share price thresholds.
Laidlaw & Company (UK) Ltd. acted as placement agent, while Lake Street Capital Markets, LLC served as financial advisor.
The securities have not been registered under the Securities Act of 1933 and were offered in a transaction exempt from registration requirements. Femasys has agreed to file a registration statement with the Securities and Exchange Commission for the resale of shares.
Femasys develops fertility and birth control solutions, including FemaSeed for infertility treatment and FemBloc for permanent birth control. The company is conducting the FINALE pivotal trial for U.S. FDA approval of FemBloc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ATLANTA - Femasys Inc. (NASDAQ:FEMY) announced today that it has entered into a securities purchase agreement for a $30 million private placement with accredited investors, according to a press release statement.
The financing is led by new institutional investor Nantahala Capital, with participation from healthcare-focused funds including Rosalind Advisors, Inc., and members of Femasys management. The transaction is expected to close on or around Sunday.
Under the agreement, the company is selling 9,374,999 shares of common stock and pre-funded warrants, along with accompanying warrants to purchase 18,749,998 shares of common stock. The purchase price per share and accompanying warrants is $3.20, while pre-funded warrants are priced at $3.1999.
Each investor will receive two accompanying warrants with a three-year term for each share or pre-funded warrant purchased. The accompanying warrants have an exercise price of $2.95 per share. Pre-funded warrants carry an exercise price of $0.0001 per share.
If all warrants are exercised for cash, the company would receive up to an additional $60 million. The milestone warrants become exercisable 12 months after closing and expire 45 days after the company achieves specified conditions, including reported U.S. revenue of at least $1.5 million in any fiscal quarter and meeting certain share price thresholds.
Laidlaw & Company (UK) Ltd. acted as placement agent, while Lake Street Capital Markets, LLC served as financial advisor.
The securities have not been registered under the Securities Act of 1933 and were offered in a transaction exempt from registration requirements. Femasys has agreed to file a registration statement with the Securities and Exchange Commission for the resale of shares.
Femasys develops fertility and birth control solutions, including FemaSeed for infertility treatment and FemBloc for permanent birth control. The company is conducting the FINALE pivotal trial for U.S. FDA approval of FemBloc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。